Stakeholders at stake in implementing personalized healthcare

Prof Alain van Gool

Bootcamp Student meets innovation 27 Nov 2015

My background

8 years academia (NL, UK)

(molecular mechanisms of disease)

13 years pharma (EU, USA, Asia)

(biomarkers, Omics)

4 years med school (NL)

(personalized healthcare, Omics, biomarkers)

4 years applied research institute (NL, EU)

(biomarkers, personalized health, nutrition)

A person / citizen / family man

(adventures in EU, USA, Asia)

1991-1996 (PhD)

1996-1998 (post-doc)

2009-2012 (visiting prof)

1999-2007 2007-2009 2009-2011

2011-now

2011-now (prof)

2

Professor of Personalized Healthcare Head Radboud Center for Proteomics, Glycomics and Metabolomics Coordinator Radboud Technology Centers

Senior Scientist Integrator Biomarkers

Collaboration towards teamwork

3

• Not easy to achieve

• If done well: great energy, good focussed output

• If done badly: ineffective, no desired output

Collaboration starts with understanding

4

• Stakeholders can have (very) different interests, motivations, struggles

• Select your discussion partner

• Know his/her background

• Respect

• Discuss with open questions

• Listen, Learn, Adapt

• Be open for input & critisism

• Maintain big picture goal

• Aim for 1+1=3

Semantics

5

Translational science

• Molecular Biologist - Biochemistry to cell

• Pharmacologist - Cell to animal

• Clinical pharmacologist - Animal to man

• Clinician - Healthy person to patient

• Enterpreneur - Innovation beta version to product

Preclinical Clinical

• Cell, animal - Man

• Healthy person - Patient

• Research - Implemented product

Semantics

6

Intervention

• Pharmaceutical drug developer - Drug

• Psychologist - Provide right information to individual so he/she can take better informed decision about own health

Innovation

• Patent

• New product

• New implemented procedure

Part of my world • Glycoproteomics profiling in plasma • Detection of ~12.000 unique deconvoluted monoisotopic masses

per single analysis (> 50% are glycopeptides)

500

1000

1500

2000

m/z

5 10 15 20 25 30 35 40 Time [min]

Proof of principle study:

7

Part of my world

8

Systems biology view on metabolic health and disease to map pharma-nutrition effects

Part of my world

9

Radboudumc Technology Centers

About 250 dedicated people working in 18 Technology Centers, ~2000 users (internal, external), ~140 consortia www.radboudumc.nl/research/technologycenters/

Part of my world Functional networks in region, nation, Europe, world

10

Different worlds: molecular biologist and patient

“I’m afraid you’re

suffering from an

increased IL-1β and

an aberrant miR843

expression”

Adapted from:

?

11

People are more than molecular pathways

Source: Barabási 2007 NEJM 357; 4}

• People are different • Different networks and influences • Different risk factors • Different preferences

12

Personalized Healthcare @ Radboudumc

People are different Stratification by multilevel diagnosis

+ Patient’s preference of treatment

Exchange experiences in care communities Select personalized therapy

Population

Man

Molecule

Alain van Gool, Workshop Neuroinformatics and personalized health care , Nijmegen, 26 Nov 2015 13

Most important in Personalized Healthcare:

Focus on the end user: the patient / citizen

14

14

Lab values Clinical outcomes

Pain Mobility Fatigue

INTEGRATE-HTA

Objectives patient and clinican may be different

R van Hoorn, W Kievit, M Tummers, GJ van der Wilt

How to do optimal shared decision making?

Intervention

Many stakeholders in Personalized Healthcare

16

Stakeholders

17

www.projectsmart.co.uk/

18

Stakeholders in science

19

Stakeholders in society

20

Young stakeholders

21

Stakeholders in education

Minor Personalized Health(care)

22

• Opinion: Team work is only possible when you understand your partner’s motivation

• Task: get to know the stakeholders in Personalized Health(care)

o Patient o Clinician o Nurse o Basic researcher o Applied researcher o Care provider o Health insurer o Pharmaceutical developer o Nutrition developer o Health economist Teams Background check 10 Question-based interviews

Minor Personalized Health(care)

23

• Task: pitch your 2025 innovation in Personalized Health(care)

+ involvement of stakeholders

Collaboration starts with understanding

24

• Stakeholders can have (very) different interests, motivations, struggles

• Select your discussion partner

• Know his/her background

• Respect

• Discuss with open questions

• Listen, Learn, Adapt

• Be open for input & critisism

• Maintain big picture goal

• Aim for 1+1=3

Collaboration

Available as innovation expert

Personalized Healthcare

Biomarkers

Molecular biology

Genomics / proteomics

www.radboudumc.nl/personalizedhealthcare

www.radboudumc.nl/research/technologycenters

www.radboudresearchfacilities.nl

www.linkedIn.com

www.slideshare.net/alainvangool

alain.vangool@radboudumc.nl

alain.vangool@tno.nl

26

Collaboration

Communication

Innovation

Validation

Pharmaceutical industry

Academia

Hospital

Spin-off companies